文献速递基础与转化研究临床试验与 GCP

多抗原靶向T细胞治疗多发性骨髓瘤的安全性与临床效果

The safety and clinical effects of administering a multiantigen-targeted T cell therapy to patients with multiple myeloma.
PubMed 文献 · Sci Transl Med · 2020-01-01

研究从23例多发性骨髓瘤患者扩增多克隆T细胞,富集针对PRAME、SSX2、MAGEA4、Survivin和NY-ESO-1五个靶点的天然T细胞受体反应性T细胞;向21例患者输注递增剂量(0.5×10^7至2×10^7细胞/m2)的非工程化多抗原特异性T细胞,耐受良好,仅出现两例短暂的III级输注相关不良事件,活动性复发或难治患者无进展生存期长于预期,3例获客观缓解并检出功能性TAA反应性T细胞克隆型。

要点

  • 非工程化多抗原特异性T细胞输注耐受良好,仅两例短暂III级输注相关不良事件。
  • 活动性复发或难治MM患者无进展生存期长于预期。
  • 3例客观缓解者检出输注产品来源的功能性TAA反应性T细胞克隆型。

核心结论

  • 多抗原靶向T细胞疗法在高危、复发或难治性多发性骨髓瘤患者中耐受良好,并显示临床获益信号。

研究设计与样本

  • 从23例MM患者扩增多克隆T细胞,富集对PRAME、SSX2、MAGEA4、Survivin和NY-ESO-1五个TAA有天然TCR反应性的T细胞。
  • 向21例MM患者输注递增剂量(0.5×10^7至2×10^7细胞/m2)的非工程化mTAA特异性T细胞。
  • 21例中9例为高危复发风险(中位3线既往治疗),12例为活动性复发或难治疾病(中位3.5线既往治疗)。

主要发现

  • 细胞耐受良好,仅两例短暂的III级输注相关不良事件。
  • 活动性复发或难治骨髓瘤患者无进展生存期长于预期。
  • 3例患者获客观缓解,同时检出源自输注mTAA产品的功能性TAA反应性T细胞克隆型。

临床怎么用

  • 多抗原特异性T细胞疗法可作为高危、复发或难治MM的潜在治疗选择,需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Multiple myeloma (MM) is an almost always incurable malignancy of plasma cells. Despite the advent of new therapies, most patients eventually relapse or become treatment-refractory. Consequently, therapies with nonoverlapping mechanisms of action that are nontoxic and provide long-term benefit to patients with MM are greatly needed. To this end, we clinically tested an autologous multitumor-associated antigen (mTAA)-specific T cell product for the treatment of patients with high-risk, relapsed or refractory MM. In this study, we expanded polyclonal T cells from 23 patients with MM. T cells whose native T cell receptors were reactive toward five myeloma-expressed target TAAs (PRAME, SSX2, MAGEA4, Survivin, and NY-ESO-1) were enriched ex vivo. To date, we have administered escalating doses of these nonengineered mTAA-specific T cells (0.5 × 107 to 2 × 107 cells/m2) to 21 patients with MM, 9 of whom were at high risk of relapse after a median of 3 lines of prior therapy and 12 with active, relapsed or refractory disease after a median of 3.5 prior lines. The cells were well tolerated, with only two transient, grade III infusion-related adverse events. Furthermore, patients with active relapsed or refractory myeloma enjoyed a longer than expected progression-free survival and responders included three patients who achieved objective responses concomitant with detection of functional TAA-reactive T cell clonotypes derived from the infused mTAA product.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Lulla PD, Tzannou I, Vasileiou S, et al. The safety and clinical effects of administering a multiantigen-targeted T cell therapy to patients with multiple myeloma. Sci Transl Med. 2020. PMID: 32727914. doi:10.1126/scitranslmed.aaz3339

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。